Literature DB >> 20852005

Effect of number of replicate electrocardiograms recorded at each time point in a thorough QT study on sample size and study cost.

Mili Natekar1, Pooja Hingorani, Pallavi Gupta, Dilip R Karnad, Snehal Kothari, Michiel de Vries, Troy Zumbrunnen, Dhiraj Narula.   

Abstract

In a "thorough QT/QTc" (TQT) study, several replicate electrocardiograms (ECGs) are recorded at each time point to reduce within-subject variability. This decreases the sample size but increases the cost of ECG analysis. To determine the most cost-effective number of ECG replicates, the authors retrospectively analyzed data from the placebo and moxifloxacin arms of a TQT study with crossover design. Six replicate ECGs were recorded at 7 time points on day -1 (baseline day), day 1, and day 3 in 124 normal healthy volunteers who were randomized to receive moxifloxacin or placebo on day 1 and the other treatment on day 3. QT interval was corrected for heart rate by the Fridericia (QTcF) and individual subject-specific (QTcI) formulas. Within-subject and between-subject standard deviations for QTcF obtained by repeated-measures analysis of covariance were 9.5 and 13.3 milliseconds with 1 replicate; 7.8 and 12.7 milliseconds with 2 replicates; 7.3 and 12.3 milliseconds with 3 replicates; 6.9 and 12.2 milliseconds with 4 replicates; 6.8 and 11.9 milliseconds with 5 replicates; and 6.6 and 11.8 milliseconds with 6 replicates. Within- and between-subject variance with QTcI also declined with increasing replicates. Sample size benefit based on these estimates was negligible beyond 4 replicates. The study cost was least with 3 or 4 replicates, depending on per-ECG and per-subject costs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20852005     DOI: 10.1177/0091270010376962

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  6 in total

1.  Detecting moxifloxacin-induced QTc prolongation in thorough QT and early clinical phase studies using a highly automated ECG analysis approach.

Authors:  Gopi Krishna Panicker; Dilip R Karnad; Pramod Kadam; Fabio Badilini; Anil Damle; Snehal Kothari
Journal:  Br J Pharmacol       Date:  2016-03-04       Impact factor: 8.739

Review 2.  Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

3.  Establishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study.

Authors:  Rashmi R Shah; Pierre Maison-Blanche; Thierry Duvauchelle; Philippe Robert; Emmanuel Denis
Journal:  Eur J Clin Pharmacol       Date:  2015-10-01       Impact factor: 2.953

4.  Electrocardiographic data quality in thorough QT/QTc studies.

Authors:  Lars Johannesen; Christine Garnett; Marek Malik
Journal:  Drug Saf       Date:  2014-03       Impact factor: 5.606

5.  Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure-Response Analysis.

Authors:  Chakradhar Lagishetty; Katy Moore; Peter Ackerman; Cyril Llamoso; Mindy Magee
Journal:  Clin Transl Sci       Date:  2020-03-19       Impact factor: 4.689

6.  The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.

Authors:  Arne Ring; Tobias Brand; Sreeraj Macha; Kerstin Breithaupt-Groegler; Gudrun Simons; Beate Walter; Hans J Woerle; Uli C Broedl
Journal:  Cardiovasc Diabetol       Date:  2013-04-24       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.